This company is now a one-trick pony, with superior drugs like Nexavar showing greater efficacy over a much wider range of conditions.
Most analysts are rating this one a strong sell.
This company is now a one-trick pony, with superior drugs like...
Add to My Watchlist
What is My Watchlist?